Loading…
Plasma levels of plasminogen activator inhibitor‐1 and bleeding phenotype in patients with von Willebrand disease
Introduction von Willebrand disease (VWD) is the most common inherited bleeding disorder. In VWD patients, large variations in bleeding tendency are observed, which cannot be completely explained by the variation in von Willebrand factor levels or activities. Thus, there must be additional factors,...
Saved in:
| Published in: | Haemophilia : the official journal of the World Federation of Hemophilia 2017-05, Vol.23 (3), p.437-443 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3886-874b82fad92fc60ab778c25058b5d3a9ff873c3d71982c26a673b245803b994e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3886-874b82fad92fc60ab778c25058b5d3a9ff873c3d71982c26a673b245803b994e3 |
| container_end_page | 443 |
| container_issue | 3 |
| container_start_page | 437 |
| container_title | Haemophilia : the official journal of the World Federation of Hemophilia |
| container_volume | 23 |
| creator | Abdul, S. Boender, J. Malfliet, J. J. M. C. Eikenboom, J. Fijn van Draat, K. Mauser‐Bunschoten, E. P. Meijer, K. Meris, J. Laros‐van Gorkom, B. A. P. Bom, J. G. Leebeek, F. W. G. Rijken, D. C. Uitte de Willige, S. Fijnvandraat, K Coppens, M Kors, A Jonkers, H Boersma, R Beckers, A Granzen, B Tamminga, J Linden, W Ypma, F Smiers, W Brons, P Nijziel, M Cnossen, H |
| description | Introduction
von Willebrand disease (VWD) is the most common inherited bleeding disorder. In VWD patients, large variations in bleeding tendency are observed, which cannot be completely explained by the variation in von Willebrand factor levels or activities. Thus, there must be additional factors, for instance, changes in fibrinolysis that have an effect on the variation in bleeding tendency in VWD patients.
Aim
To investigate whether plasminogen activator inhibitor‐1 (PAI‐1) level influences the variation in bleeding tendency in VWD patients.
Methods
PAI‐1 antigen levels were measured in the plasma of 633 patients with moderate or severe VWD who participated in the ‘Willebrand in the Netherlands’ (WiN) study, a nationwide multicentre cross‐sectional study. Bleeding severity was assessed using the Tosetto bleeding score.
Results
PAI‐1 levels increased with age (Spearman's rho: 0.225, P |
| doi_str_mv | 10.1111/hae.13206 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1878824730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1878824730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-874b82fad92fc60ab778c25058b5d3a9ff873c3d71982c26a673b245803b994e3</originalsourceid><addsrcrecordid>eNp10ctKxDAUBuAgiveFLyABN7qo5tKm6VLEGwi6UFyGpD11IpmkNp2R2fkIPqNPYuaiC8FscghffpJzEDqg5JSmdTbScEo5I2INbVMuiowVVKzP64JmklGxhXZifCVkgTbRFpOcCFrJbRQfnI5jjR1MwUUcWtzND6wPL-Cxrgc71UPosfUja2yqvj4-Kda-wcYBNNa_4G4EPgyzDhLCnR4s-CHidzuM8DR4_GydA9PPrzQ2go6whzZa7SLsr_Zd9HR1-Xhxk93dX99enN9lNZdSZLLMjWStbirW1oJoU5ayZgUppCkarqu2lSWveVOmj7CaCS1KblheSMJNVeXAd9HxMrfrw9sE4qDGNtbgnPYQJlFRWUrJ8pKTRI_-0Ncw6X16naIVI7mkMs-TOlmqug8x9tCqrrdj3c8UJWo-CZUmoRZNTvZwlTgxY2h-5U_rEzhbgnfrYPZ_kro5v1xGfgOVDJM1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1920481844</pqid></control><display><type>article</type><title>Plasma levels of plasminogen activator inhibitor‐1 and bleeding phenotype in patients with von Willebrand disease</title><source>Wiley</source><creator>Abdul, S. ; Boender, J. ; Malfliet, J. J. M. C. ; Eikenboom, J. ; Fijn van Draat, K. ; Mauser‐Bunschoten, E. P. ; Meijer, K. ; Meris, J. ; Laros‐van Gorkom, B. A. P. ; Bom, J. G. ; Leebeek, F. W. G. ; Rijken, D. C. ; Uitte de Willige, S. ; Fijnvandraat, K ; Coppens, M ; Kors, A ; Jonkers, H ; Boersma, R ; Beckers, A ; Granzen, B ; Tamminga, J ; Linden, W ; Ypma, F ; Smiers, W ; Brons, P ; Nijziel, M ; Cnossen, H</creator><creatorcontrib>Abdul, S. ; Boender, J. ; Malfliet, J. J. M. C. ; Eikenboom, J. ; Fijn van Draat, K. ; Mauser‐Bunschoten, E. P. ; Meijer, K. ; Meris, J. ; Laros‐van Gorkom, B. A. P. ; Bom, J. G. ; Leebeek, F. W. G. ; Rijken, D. C. ; Uitte de Willige, S. ; Fijnvandraat, K ; Coppens, M ; Kors, A ; Jonkers, H ; Boersma, R ; Beckers, A ; Granzen, B ; Tamminga, J ; Linden, W ; Ypma, F ; Smiers, W ; Brons, P ; Nijziel, M ; Cnossen, H ; WIN study group</creatorcontrib><description>Introduction
von Willebrand disease (VWD) is the most common inherited bleeding disorder. In VWD patients, large variations in bleeding tendency are observed, which cannot be completely explained by the variation in von Willebrand factor levels or activities. Thus, there must be additional factors, for instance, changes in fibrinolysis that have an effect on the variation in bleeding tendency in VWD patients.
Aim
To investigate whether plasminogen activator inhibitor‐1 (PAI‐1) level influences the variation in bleeding tendency in VWD patients.
Methods
PAI‐1 antigen levels were measured in the plasma of 633 patients with moderate or severe VWD who participated in the ‘Willebrand in the Netherlands’ (WiN) study, a nationwide multicentre cross‐sectional study. Bleeding severity was assessed using the Tosetto bleeding score.
Results
PAI‐1 levels increased with age (Spearman's rho: 0.225, P < 0.001) and were higher in men (23 [IQR 12–60] vs. 20 [IQR 10–44] ng mL−1 in women, P = 0.039), whereas the bleeding score was higher in women (11 [IQR 7–17] vs. 9 [IQR 5–14] ng mL−1 in men, P = 0.002). After adjustment for age and sex by stratification, PAI‐1 level and bleeding score were negatively correlated (Spearman's rho: −0.170, P = 0.017) in the group of 196 young (age ≤ 45 year) female VWD patients, accounting for 31% of our study population.
Conclusion
In young female VWD patients, we observed that low PAI‐1 levels were associated with a higher bleeding score, which may partly explain the observed variability in bleeding phenotype in VWD patients.</description><identifier>ISSN: 1351-8216</identifier><identifier>EISSN: 1365-2516</identifier><identifier>DOI: 10.1111/hae.13206</identifier><identifier>PMID: 28306198</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Age ; Aged ; Aged, 80 and over ; Bleeding ; bleeding score ; Child ; Child, Preschool ; Cohort Studies ; Female ; Fibrinolysis ; Genotype ; Health risk assessment ; Hemorrhage - complications ; Humans ; Infant ; Male ; Middle Aged ; Phenotype ; Plasma levels ; Plasminogen Activator Inhibitor 1 - blood ; Plasminogen Activator Inhibitor 1 - genetics ; Plasminogen activator inhibitors ; plasminogen activator inhibitor‐1 ; Population studies ; von Willebrand disease ; von Willebrand Diseases - blood ; von Willebrand Diseases - complications ; von Willebrand Diseases - genetics ; Von Willebrand factor ; Young Adult</subject><ispartof>Haemophilia : the official journal of the World Federation of Hemophilia, 2017-05, Vol.23 (3), p.437-443</ispartof><rights>2017 John Wiley & Sons Ltd</rights><rights>2017 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-874b82fad92fc60ab778c25058b5d3a9ff873c3d71982c26a673b245803b994e3</citedby><cites>FETCH-LOGICAL-c3886-874b82fad92fc60ab778c25058b5d3a9ff873c3d71982c26a673b245803b994e3</cites><orcidid>0000-0002-2035-4485</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhae.13206$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhae.13206$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28306198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdul, S.</creatorcontrib><creatorcontrib>Boender, J.</creatorcontrib><creatorcontrib>Malfliet, J. J. M. C.</creatorcontrib><creatorcontrib>Eikenboom, J.</creatorcontrib><creatorcontrib>Fijn van Draat, K.</creatorcontrib><creatorcontrib>Mauser‐Bunschoten, E. P.</creatorcontrib><creatorcontrib>Meijer, K.</creatorcontrib><creatorcontrib>Meris, J.</creatorcontrib><creatorcontrib>Laros‐van Gorkom, B. A. P.</creatorcontrib><creatorcontrib>Bom, J. G.</creatorcontrib><creatorcontrib>Leebeek, F. W. G.</creatorcontrib><creatorcontrib>Rijken, D. C.</creatorcontrib><creatorcontrib>Uitte de Willige, S.</creatorcontrib><creatorcontrib>Fijnvandraat, K</creatorcontrib><creatorcontrib>Coppens, M</creatorcontrib><creatorcontrib>Kors, A</creatorcontrib><creatorcontrib>Jonkers, H</creatorcontrib><creatorcontrib>Boersma, R</creatorcontrib><creatorcontrib>Beckers, A</creatorcontrib><creatorcontrib>Granzen, B</creatorcontrib><creatorcontrib>Tamminga, J</creatorcontrib><creatorcontrib>Linden, W</creatorcontrib><creatorcontrib>Ypma, F</creatorcontrib><creatorcontrib>Smiers, W</creatorcontrib><creatorcontrib>Brons, P</creatorcontrib><creatorcontrib>Nijziel, M</creatorcontrib><creatorcontrib>Cnossen, H</creatorcontrib><creatorcontrib>WIN study group</creatorcontrib><title>Plasma levels of plasminogen activator inhibitor‐1 and bleeding phenotype in patients with von Willebrand disease</title><title>Haemophilia : the official journal of the World Federation of Hemophilia</title><addtitle>Haemophilia</addtitle><description>Introduction
von Willebrand disease (VWD) is the most common inherited bleeding disorder. In VWD patients, large variations in bleeding tendency are observed, which cannot be completely explained by the variation in von Willebrand factor levels or activities. Thus, there must be additional factors, for instance, changes in fibrinolysis that have an effect on the variation in bleeding tendency in VWD patients.
Aim
To investigate whether plasminogen activator inhibitor‐1 (PAI‐1) level influences the variation in bleeding tendency in VWD patients.
Methods
PAI‐1 antigen levels were measured in the plasma of 633 patients with moderate or severe VWD who participated in the ‘Willebrand in the Netherlands’ (WiN) study, a nationwide multicentre cross‐sectional study. Bleeding severity was assessed using the Tosetto bleeding score.
Results
PAI‐1 levels increased with age (Spearman's rho: 0.225, P < 0.001) and were higher in men (23 [IQR 12–60] vs. 20 [IQR 10–44] ng mL−1 in women, P = 0.039), whereas the bleeding score was higher in women (11 [IQR 7–17] vs. 9 [IQR 5–14] ng mL−1 in men, P = 0.002). After adjustment for age and sex by stratification, PAI‐1 level and bleeding score were negatively correlated (Spearman's rho: −0.170, P = 0.017) in the group of 196 young (age ≤ 45 year) female VWD patients, accounting for 31% of our study population.
Conclusion
In young female VWD patients, we observed that low PAI‐1 levels were associated with a higher bleeding score, which may partly explain the observed variability in bleeding phenotype in VWD patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bleeding</subject><subject>bleeding score</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>Genotype</subject><subject>Health risk assessment</subject><subject>Hemorrhage - complications</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenotype</subject><subject>Plasma levels</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Plasminogen Activator Inhibitor 1 - genetics</subject><subject>Plasminogen activator inhibitors</subject><subject>plasminogen activator inhibitor‐1</subject><subject>Population studies</subject><subject>von Willebrand disease</subject><subject>von Willebrand Diseases - blood</subject><subject>von Willebrand Diseases - complications</subject><subject>von Willebrand Diseases - genetics</subject><subject>Von Willebrand factor</subject><subject>Young Adult</subject><issn>1351-8216</issn><issn>1365-2516</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp10ctKxDAUBuAgiveFLyABN7qo5tKm6VLEGwi6UFyGpD11IpmkNp2R2fkIPqNPYuaiC8FscghffpJzEDqg5JSmdTbScEo5I2INbVMuiowVVKzP64JmklGxhXZifCVkgTbRFpOcCFrJbRQfnI5jjR1MwUUcWtzND6wPL-Cxrgc71UPosfUja2yqvj4-Kda-wcYBNNa_4G4EPgyzDhLCnR4s-CHidzuM8DR4_GydA9PPrzQ2go6whzZa7SLsr_Zd9HR1-Xhxk93dX99enN9lNZdSZLLMjWStbirW1oJoU5ayZgUppCkarqu2lSWveVOmj7CaCS1KblheSMJNVeXAd9HxMrfrw9sE4qDGNtbgnPYQJlFRWUrJ8pKTRI_-0Ncw6X16naIVI7mkMs-TOlmqug8x9tCqrrdj3c8UJWo-CZUmoRZNTvZwlTgxY2h-5U_rEzhbgnfrYPZ_kro5v1xGfgOVDJM1</recordid><startdate>201705</startdate><enddate>201705</enddate><creator>Abdul, S.</creator><creator>Boender, J.</creator><creator>Malfliet, J. J. M. C.</creator><creator>Eikenboom, J.</creator><creator>Fijn van Draat, K.</creator><creator>Mauser‐Bunschoten, E. P.</creator><creator>Meijer, K.</creator><creator>Meris, J.</creator><creator>Laros‐van Gorkom, B. A. P.</creator><creator>Bom, J. G.</creator><creator>Leebeek, F. W. G.</creator><creator>Rijken, D. C.</creator><creator>Uitte de Willige, S.</creator><creator>Fijnvandraat, K</creator><creator>Coppens, M</creator><creator>Kors, A</creator><creator>Jonkers, H</creator><creator>Boersma, R</creator><creator>Beckers, A</creator><creator>Granzen, B</creator><creator>Tamminga, J</creator><creator>Linden, W</creator><creator>Ypma, F</creator><creator>Smiers, W</creator><creator>Brons, P</creator><creator>Nijziel, M</creator><creator>Cnossen, H</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2035-4485</orcidid></search><sort><creationdate>201705</creationdate><title>Plasma levels of plasminogen activator inhibitor‐1 and bleeding phenotype in patients with von Willebrand disease</title><author>Abdul, S. ; Boender, J. ; Malfliet, J. J. M. C. ; Eikenboom, J. ; Fijn van Draat, K. ; Mauser‐Bunschoten, E. P. ; Meijer, K. ; Meris, J. ; Laros‐van Gorkom, B. A. P. ; Bom, J. G. ; Leebeek, F. W. G. ; Rijken, D. C. ; Uitte de Willige, S. ; Fijnvandraat, K ; Coppens, M ; Kors, A ; Jonkers, H ; Boersma, R ; Beckers, A ; Granzen, B ; Tamminga, J ; Linden, W ; Ypma, F ; Smiers, W ; Brons, P ; Nijziel, M ; Cnossen, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-874b82fad92fc60ab778c25058b5d3a9ff873c3d71982c26a673b245803b994e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bleeding</topic><topic>bleeding score</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>Genotype</topic><topic>Health risk assessment</topic><topic>Hemorrhage - complications</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenotype</topic><topic>Plasma levels</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Plasminogen Activator Inhibitor 1 - genetics</topic><topic>Plasminogen activator inhibitors</topic><topic>plasminogen activator inhibitor‐1</topic><topic>Population studies</topic><topic>von Willebrand disease</topic><topic>von Willebrand Diseases - blood</topic><topic>von Willebrand Diseases - complications</topic><topic>von Willebrand Diseases - genetics</topic><topic>Von Willebrand factor</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdul, S.</creatorcontrib><creatorcontrib>Boender, J.</creatorcontrib><creatorcontrib>Malfliet, J. J. M. C.</creatorcontrib><creatorcontrib>Eikenboom, J.</creatorcontrib><creatorcontrib>Fijn van Draat, K.</creatorcontrib><creatorcontrib>Mauser‐Bunschoten, E. P.</creatorcontrib><creatorcontrib>Meijer, K.</creatorcontrib><creatorcontrib>Meris, J.</creatorcontrib><creatorcontrib>Laros‐van Gorkom, B. A. P.</creatorcontrib><creatorcontrib>Bom, J. G.</creatorcontrib><creatorcontrib>Leebeek, F. W. G.</creatorcontrib><creatorcontrib>Rijken, D. C.</creatorcontrib><creatorcontrib>Uitte de Willige, S.</creatorcontrib><creatorcontrib>Fijnvandraat, K</creatorcontrib><creatorcontrib>Coppens, M</creatorcontrib><creatorcontrib>Kors, A</creatorcontrib><creatorcontrib>Jonkers, H</creatorcontrib><creatorcontrib>Boersma, R</creatorcontrib><creatorcontrib>Beckers, A</creatorcontrib><creatorcontrib>Granzen, B</creatorcontrib><creatorcontrib>Tamminga, J</creatorcontrib><creatorcontrib>Linden, W</creatorcontrib><creatorcontrib>Ypma, F</creatorcontrib><creatorcontrib>Smiers, W</creatorcontrib><creatorcontrib>Brons, P</creatorcontrib><creatorcontrib>Nijziel, M</creatorcontrib><creatorcontrib>Cnossen, H</creatorcontrib><creatorcontrib>WIN study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdul, S.</au><au>Boender, J.</au><au>Malfliet, J. J. M. C.</au><au>Eikenboom, J.</au><au>Fijn van Draat, K.</au><au>Mauser‐Bunschoten, E. P.</au><au>Meijer, K.</au><au>Meris, J.</au><au>Laros‐van Gorkom, B. A. P.</au><au>Bom, J. G.</au><au>Leebeek, F. W. G.</au><au>Rijken, D. C.</au><au>Uitte de Willige, S.</au><au>Fijnvandraat, K</au><au>Coppens, M</au><au>Kors, A</au><au>Jonkers, H</au><au>Boersma, R</au><au>Beckers, A</au><au>Granzen, B</au><au>Tamminga, J</au><au>Linden, W</au><au>Ypma, F</au><au>Smiers, W</au><au>Brons, P</au><au>Nijziel, M</au><au>Cnossen, H</au><aucorp>WIN study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma levels of plasminogen activator inhibitor‐1 and bleeding phenotype in patients with von Willebrand disease</atitle><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle><addtitle>Haemophilia</addtitle><date>2017-05</date><risdate>2017</risdate><volume>23</volume><issue>3</issue><spage>437</spage><epage>443</epage><pages>437-443</pages><issn>1351-8216</issn><eissn>1365-2516</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Introduction
von Willebrand disease (VWD) is the most common inherited bleeding disorder. In VWD patients, large variations in bleeding tendency are observed, which cannot be completely explained by the variation in von Willebrand factor levels or activities. Thus, there must be additional factors, for instance, changes in fibrinolysis that have an effect on the variation in bleeding tendency in VWD patients.
Aim
To investigate whether plasminogen activator inhibitor‐1 (PAI‐1) level influences the variation in bleeding tendency in VWD patients.
Methods
PAI‐1 antigen levels were measured in the plasma of 633 patients with moderate or severe VWD who participated in the ‘Willebrand in the Netherlands’ (WiN) study, a nationwide multicentre cross‐sectional study. Bleeding severity was assessed using the Tosetto bleeding score.
Results
PAI‐1 levels increased with age (Spearman's rho: 0.225, P < 0.001) and were higher in men (23 [IQR 12–60] vs. 20 [IQR 10–44] ng mL−1 in women, P = 0.039), whereas the bleeding score was higher in women (11 [IQR 7–17] vs. 9 [IQR 5–14] ng mL−1 in men, P = 0.002). After adjustment for age and sex by stratification, PAI‐1 level and bleeding score were negatively correlated (Spearman's rho: −0.170, P = 0.017) in the group of 196 young (age ≤ 45 year) female VWD patients, accounting for 31% of our study population.
Conclusion
In young female VWD patients, we observed that low PAI‐1 levels were associated with a higher bleeding score, which may partly explain the observed variability in bleeding phenotype in VWD patients.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28306198</pmid><doi>10.1111/hae.13206</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2035-4485</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-8216 |
| ispartof | Haemophilia : the official journal of the World Federation of Hemophilia, 2017-05, Vol.23 (3), p.437-443 |
| issn | 1351-8216 1365-2516 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1878824730 |
| source | Wiley |
| subjects | Adolescent Adult Age Aged Aged, 80 and over Bleeding bleeding score Child Child, Preschool Cohort Studies Female Fibrinolysis Genotype Health risk assessment Hemorrhage - complications Humans Infant Male Middle Aged Phenotype Plasma levels Plasminogen Activator Inhibitor 1 - blood Plasminogen Activator Inhibitor 1 - genetics Plasminogen activator inhibitors plasminogen activator inhibitor‐1 Population studies von Willebrand disease von Willebrand Diseases - blood von Willebrand Diseases - complications von Willebrand Diseases - genetics Von Willebrand factor Young Adult |
| title | Plasma levels of plasminogen activator inhibitor‐1 and bleeding phenotype in patients with von Willebrand disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T09%3A29%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20levels%20of%20plasminogen%20activator%20inhibitor%E2%80%901%20and%20bleeding%20phenotype%20in%20patients%20with%20von%20Willebrand%20disease&rft.jtitle=Haemophilia%20:%20the%20official%20journal%20of%20the%20World%20Federation%20of%20Hemophilia&rft.au=Abdul,%20S.&rft.aucorp=WIN%20study%20group&rft.date=2017-05&rft.volume=23&rft.issue=3&rft.spage=437&rft.epage=443&rft.pages=437-443&rft.issn=1351-8216&rft.eissn=1365-2516&rft_id=info:doi/10.1111/hae.13206&rft_dat=%3Cproquest_cross%3E1878824730%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3886-874b82fad92fc60ab778c25058b5d3a9ff873c3d71982c26a673b245803b994e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1920481844&rft_id=info:pmid/28306198&rfr_iscdi=true |